- Conditions
- HIV Infections
- Interventions
- ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 4,205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Alpelisib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more
- Conditions
- Tinnitus
- Interventions
- AM-101 0.81 mg/mL, Placebo
- Drug
- Lead sponsor
- Auris Medical, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- Gainsville, Florida • Kansas City, Kansas • Louisville, Kentucky + 2 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Secukinumab (AIN457), Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 25
- States / cities
- Peoria, Arizona • Santa Monica, California • Upland, California + 20 more
- Conditions
- Study Conducted in Healthy Volunteers
- Interventions
- lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Edgewater, Florida
- Conditions
- Lyme Borreliosis
- Interventions
- VLA15, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Warren Township, New Jersey • Cortland, New York • Horseheads, New York + 3 more
- Conditions
- Anterior Cruciate Ligament
- Interventions
- Gel-One, Saline Placebo
- Drug · Other
- Lead sponsor
- Cale Jacobs, PhD
- Other
- Eligibility
- 14 Years to 33 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Glabellar Rhytides, Frown Lines Between the Eyebrows
- Interventions
- Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
- Drug
- Lead sponsor
- Mentor Worldwide, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Asthma
- Interventions
- Placebo, Brodalumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Chronic Kidney Diseases
- Interventions
- COR-001, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Cullman, Alabama • Maitland, Florida • Sunrise, Florida + 6 more
- Conditions
- Urinary Incontinence,Stress, Urinary Incontinence
- Interventions
- Platelet-rich plasma injection
- Procedure
- Lead sponsor
- Annah J. Vollstedt
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Warts
- Interventions
- Vitamin D3, Placebo
- Drug
- Lead sponsor
- Stephen P. Merry
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
- Interventions
- Intravenous immunoglobulin, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- MET097 Injection, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 29
- States / cities
- Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more
- Conditions
- Liver Fibrosis Due to NASH
- Interventions
- Placebo, SIM
- Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
- Conditions
- Systemic Sclerosis
- Interventions
- RO7303509, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Palo Alto, California • New York, New York • Dallas, Texas
- Conditions
- Healthy Participants
- Interventions
- AZD5148, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Anniston, Alabama • Glendale, California • Baltimore, Maryland + 1 more
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Interventions
- MYDICAR Phase 1, MYDICAR Phase 2, Placebo Phase 2 only
- Genetic
- Lead sponsor
- Celladon Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 4
- States / cities
- La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more
- Conditions
- Urinary Bladder, Overactive, Pelvic Organ Prolapse
- Interventions
- OnabotulinumtoxinA 100 UNT, Injectable saline
- Drug · Other
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteoarthritis, Knee
- Interventions
- SI-613, Placebo
- Combination Product
- Lead sponsor
- Seikagaku Corporation
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Miami, Florida • Newton, Kansas + 6 more
- Conditions
- Smallpox
- Interventions
- MVA Smallpox Vaccine, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 38 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • St Louis, Missouri
- Conditions
- Alcohol Dependence, Alcohol Use Disorder
- Interventions
- XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York